Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2025-12-17

Clinical Trial Update: VE202 in Patients With Mild-to-Moderate Ulcerative Colitis [Phase 2]

View source ↗

Summary

A Phase 2 trial of VE202 in Ulcerative Colitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VE202

Snippet

Sponsor: Vedanta Biosciences, Inc. | Conditions: Ulcerative Colitis, Colitis, Ulcerative | Phase 2 | Status: TERMINATED